Articles

P.07 EXCELLENT SURVIVAL OUTCOMES FOR NET PATIENTS TREATED WITHIN NETWERK, A COLLABORATIVE ENETS CENTER OF EXCELLENCE

BJMO - 12, issue 3, february 2018

T. Vandamme MD, PhD, Isabelle Maurissen , W. Lybaert MD, Marc Simoens , P. Abrams , A. Driessen MD, PhD, B. Op de Beeck , Wim Demey MD, T. Rondou , M. Ulenaers , G. Vanhoutte , Marc Peeters , Steering Committee , NET-specialists

Read more

P.08 A prospective study on the impact of a NET specific multidisciplinary tumor board on individual treatment plans

BJMO - 2017, issue 3, february 2017

W. Lybaert MD, T. Vandamme MD, PhD, M. Simoens , I. Dero MD, Wim Demey MD, T. Rondou , A. Cuypers , P. Abrams , C. Mattelaer , A. Driessen MD, PhD, B. Op de Beeck , O. D’Archambeau , G. Roeyen MD, PhD, L. De Backer , M. Peeters MD, PhD, NET specialists NETwerk Steering Committee

Read more

RAS-testing in colorectal cancer: Belgian guidelines

BJMO - volume 9, issue 5, september 2015

A. Jouret-Mourin MD, PhD, C. Cuvelier MD, PhD, P. Demetter MD, PhD, N. D’Haene MD, PhD, A. Driessen MD, PhD, A. Hoorens MD, PhD, N. Nagy MD, X. Sagaert MD, P. Pauwels MD, PhD, On behalf of the Working Group of Digestive Pathology and the Belgian Society of Pathology.

There is an urgent need for predictive biomarkers in several cancers. In colorectal cancers, KRAS exon 2 mutation analyses were mandatory when considering anti-epidermal growth factor antibody therapy with agents such as cetuximab or panitumumab. However, since the introduction of this testing, a cohort of patients still did not appear to benefit from this therapy. Recently, additional testing for KRAS exon 3 and 4, and NRAS considerably improved the predictive power for therapy success. Therefore, an update of the Belgian guidelines for RAS testing was urgently needed.

(BELG J MED ONCOL 2015;9(5):183–90)

Read more
X